

12 May 2020

## Questionnaire to Sanofi Pasteur on COVID-19 Vaccine

Thank you for the constructive discussion held on 11 May on Sanofi Pasteur plans for the development, production and introduction of a vaccine for prophylaxis against COVID-19. As discussed, we would be grateful if you could reply to the following questions by **Tuesday 19 May close of business**.

Insofar as the information provided by you contains business secrets, your information will obviously be kept confidential (see Article 339 TFEU).

Our answers refer throughout to the Baculovirus recombinant protein vaccine.


### Vaccine in Development





Production Capacities







Agreements for the Production of the Vaccine



Filling and further Steps for the Finalisation of the Production





Marketing and Distribution



Administration of the vaccine



Cooperation Agreements

[Redacted content]

Overall Time-frame

[Redacted content]	
[Redacted content]	[Redacted content]
[Redacted content]	[Redacted content]
[Redacted content]	[Redacted content]
[Redacted content]	[Redacted content]
[Redacted content]	[Redacted content]
[Redacted content]	[Redacted content]

Main Risks for the Successful Development and Production



[Redacted content]

Agreements with Government and International Organisations

[Redacted content]



Documents



Financing -



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]




[REDACTED]


[REDACTED]

[REDACTED]

Liability



## Regulatory Flexibility





Looking to the Future



